Sangamo Archives -

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles

Gene editing: beyond the hype

https://pharmaphorum.com/r-d/views-analysis-r-d/genome-editing-sangamo-beyond-the-hype/

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and

Biogen and Sangamo work on Parkinson’s and Alzheimer’s gene therapies

https://pharmaphorum.com/news/biogen-and-sangamo-work-on-parkinsons-and-alzheimers-gene-therapies/

We talk to Duncan McKay, senior vice president and general manager, Europe of Sangamo Therapeutics, about the future

Q&A: Sangamo’s Duncan McKay on genomic medicines

https://pharmaphorum.com/views-analysis-market-access/qa-sangamos-duncan-mckay-on-genomic-medicines/

Two pioneers in the parallel technologies of cell therapy and gene therapy have come together in an ambitious

Kite and Sangamo come together in $3bn cancer gene editing alliance

https://pharmaphorum.com/views-analysis-oncology/kite-sangamo-come-together-3bn-cancer-gene-editing-alliance/

The trial of Sangamo’s gene-editing treatment for a rare and debilitating disease has got off to a good

No safety concerns so far in Sangamo’s groundbreaking gene-editing trial

https://pharmaphorum.com/news/no-safety-concerns-far-sangamos-groundbreaking-gene-editing-trial/

Sangamo Therapeutics has been granted a fast track designation from the FDA for SB-525, its gene therapy candidate

Sangamo and new gene therapy partner Pfizer lifted by FDA fast track

https://pharmaphorum.com/news/sangamo-new-gene-therapy-partner-pfizer-lifted-fda-fast-track/

Sangamo